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Secrets of a cell's transformation to a cancerous state are coming to 
light through investigations into the nature of oncogenes. Gail E. Sonen-
shein, Ph.D., in the BUSM Department of Biochemistry, is studying the 
way myc—one of 20 oncogenes—operates. See story on page 3. 
Researchers find 
probable cause of 
autism; may solve 
40-year puzzle 
^ ' - ^on ths of painstaking research has 
Jlowed a Boston University School 
of Medicine researcher to find what 
probably is the solution to one of the 
"kingpuzzles in pediatric neurol-
ogy"—the cause of autism. 
Thomas L Kemper, M.D., a pro-
fessor of neurology (neuropathology) 
and anatomy at BUSM, along with 
co-investigator Margaret Bauman, 
M.D., of Massachusetts General 
Hospital, has found a brain abnor-
mality that may help to explain the 
disorder. Scientists have been strug-
gling to find the cause of autism, a 
baffling condition in which children 
withdraw into their own private world, 
since it was recognized as a syn-
drome in 1943. 
The researchers' results, if con-
firmed, will allow other scientists to 
consider new ways to study, and 
possibly to treat, autism. 
According to Kemper, these find-
ings also take a tremendous emo-
tional burden off parents of autistic 
children who have been told their 
children are autistic because the chil-
^ dren did not receive enough emo-
.ional stimulation when they were 
babies. This was the prevailing the-
ory on the cause of autism until the 
mid-1970s, and scientists have not 
had hard evidence to dispute this 
continued on page 2 
A painstaking study of a brain cut into more than 3,000 slices, some of which are pictured here, 
has allowed a BUSM researcher to find defects that may explain the cause of autism. (Photo by 
Bradford F. Herzog) 
20-year VA study of 2,000 males 
examines unknowns of aging process 
Everyone has seen an elderly rela-
tive or friend suffer from various age-
related ailments: increasing physical 
infirmities, lowered resistance to dis-
ease, the weakening or possible loss 
of mental function. But until recently, 
the medical community has focused 
most of its attention on the problems 
of pathological, or non-normal, aging. 
The factors and processes that influ-
ence normal aging have been left 
largely unexplored. 
A large interdisciplinary study 
headed by Boston University School 
of Medicine researcher Pantel S. 
Vokonas, M.D., may help to solve 
many of the unknowns attached to 
normal human aging. 
The Veterans Administration Nor-
mative Aging Study (MAS), which 
began in 1963, has followed continu-
ously the progress of 2,000 initially 
healthy men from the Greater Boston 
area. The study, funded by the VA 
with additional support from the 
National Institutes of Health, was 
undertaken to determine the normal 
patterns of aging and the precursors 
of diseases of aging, as well as the 
influence of these diseases on the 
aging process, according to 
continued on page 5 
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Autism study... 
continued from page 1 
theory until now. 
"I don't know how many mothers 
I've talked to who were relieved to 
know that they did nothing to cause 
the disorder in their children," said 
Kemper, who also is director of neu-
ropathology at Boston City Hospital, 
a principal teaching hospital of 
BUSM. 
Autism affects four or five of every 
10,000 children; males outnumber 
females four to one. Autisic children 
often develop normally through their 
first year of life. They then withdraw 
from others; they do not learn lan-
guage and often engage in monoto-
nous, repetitious behaviors. For 
example, a child may shake his head 
or bang his fist for hours. 
Though Kemper, a BUSM faculty 
member since 1975, has wanted to 
study the brain of an autistic person 
for some time, he had trouble both 
finding a qualified co-investigator 
with the time needed for such a proj-
ect and obtaining a suitable brain. 
"Finding a brain that has sufficient 
documentation to satisfy the scientific 
community that you actually are 
studying a brain of an autistic person 
is difficult. Also, it's not a fatal dis-
ease, so there are not many brains 
available," explained Kemper. 
Finally, through N. Paul Rosman, 
M.D., a professor of pediatrics and 
neurology at BUSM, Kemper 
acquired the brain of an autistic man. 
The brain was cut into more than 
3,000 slices, each only 35 microns 
thick (about one-twentieth as thick as 
a human hair). The brain of a man 
without the disorder was cut in 
exactly the same manner to use as a 
comparison. 
Kemper then teamed with Bau-
man, an assistant neurologist at 
MGH, and the two began the year-
long task of comparing the two 
brains. 
"We went through the entire brain. 
We essentially looked at each of the 
hundreds of identified areas of the 
brain," said Kemper. 
In their study the researchers used 
a special microscope that enabled 
them to see exactly the same area of 
both the autistic brain and the "nor-
mal" brain side by side, making for 
more accurate comparison. 
"If you just look at the sections 
with your bare eye, you see very lit-
tle. And even if you look at them 
under the microscope, without an 
exact comparison you see very little," 
said Kemper. "That's probably why 
people didn't see the defect in the 
past." 
When the researchers found areas 
in the autistic brain they thought dif-
fered from the "normal" brain, Bau-
man counted the cells in those areas 
to check the differences. "That's 
where the time came in. Dr. Bauman 
actually counted the density of the 
cells," said Kemper. 
The researchers also did cell 
counts in areas that appeared to be 
Thomas L. Kemper, M.D., shown here 
examining brain siices, has found a brain 
abnormality that may help to explain the 
cause of autism. (Photo by Bradford F. 
Herzog) 
normal, but were suspected of being 
related to autism. 
Through this tedious examination, 
Kemper and Bauman found two 
areas of the autistic brain in which 
there were abnormalities—the limbic 
system and the cerebellum, located 
in the base of the brain. 
In the limbic system, abnormalities 
were spotted in the amygdala, the 
hippocampus and areas closely 
related to them. These areas of the 
brain control memory, emotion and 
motivation. 
"The cells were abnormally small 
and abnormally tightly packed 
together. It gives the appearance of 
a failure of normal development or a 
brain of a much younger person. 
Exactly what age it would correspond 
to, we don't know yet," said Kemper.^ 
In the cerebellum, the brain area 
that controls coordination of move-
ment, there was a loss of nerve 
cells, said Kemper. "The form of the 
defect in the cerebellum allows us to 
conclude that this abnormality very 
likely developed before 30 weeks of 
gestation, well before birth," he 
explained. 
Kemper said behaviors controlled 
by these abnormal areas, especially 
memory, seem very closely related 
to the problems of autistic children. 
"The clinical defects are in inter-
personal relationships, memory and 
abnormal behaviors. The anatomical 
defects found in the brain are right in 
the middle of the memory circuits. 
When you start thinking about mem-
ory and human behavior, then you're 
into language and recognizing peo-
ple. That may be the core of the 
problem." 
Of the two treatments commonly 
used on autistic children—behavioral 
modification and medication—behav-
ioral modification is by far the more 
effective, according to Kemper. 
Using this, medical personnel can 
work at teaching the children after 
modifying their abnormal behaviors. 
Medication, on the other hand, often 
merely masks or blunts the symp-
toms. 
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What makes myc tick? Researchers study 
oncogene's role in cancer development 
Kemper explained, though, that 
while behavioral modification can be 
effective, it is also very time-consum-
ing and thus very costly. "We've fol-
lowed some patients for more than 
10 years, testing them at periodic 
intervals on such skills as speech 
and language, IQ scores and mental 
ages. The striking aspect we have 
found is that they progress at a 
snail's pace," he said. 
Kemper hopes other researchers 
will be able to use these findings to 
develop better treatments for people 
with autism. 
"These findings open up autism for 
more experimental research. One 
can start using animal models of 
autism and start 'going after' the dis-
order with various treatment modes 
for manifestations of the disease to 
see which treatments are most effec-
tive. This is very important." 
Kemper recently acquired the brain 
of an autistic 10-year-old girl through 
the McLean Brain Bank, McLean 
Hospital, Belmont, Mass., and has 
applied to the National Institutes of 
Health and the Stallone Foundation 
for funds to process this brain. He 
said that if studies of three or four 
more autistic brains reveal brain 
defects similar to those he and Bau-
man found, then he will be satisfied 
with the validity of the findings. 
"The knowledge of what causes 
autism will allow us to think about 
how the disease could have come 
about. Hopefully this will allow scien-
tists to recognize similar diseases 
and see where they fit in the spec-
trum of abnormal brain development. 
That's one of the most gratifying 
things about this work," said Kemper. 
— Paul D. Vaskas 
Suggested Further Readings 
1. American Psychiatric Association Diagnos-
tic and Statistical Manual of Mental Disor-
ders, Edition III. The Psychiatric Associa-
tion, 1980. 
2. Bauman, M.L. and Kemper, T.L.: The brain 
in infantile autism: A histoanatomic case 
report. Neurology 34: 275, 1984. 
When oncogenes first were discov-
ered more than a decade ago, many 
researchers saw them as foreign ele-
ments that infiltrated a person's 
genetic code through viral infection, 
then altered normal cell function and 
caused tumors. 
Since then, oncogene research 
has progressed rapidly, producing 
many exciting surprises. One thing 
now is clear: oncogenes are not nec-
essarily outside invaders. Proto-
oncogenes exist within the normal 
genetic makeup of almost all cells— 
animal or vegetable. These genes 
are fundamental and their persist-
ence throughout evolution suggests 
they play a crucial role in normal cell 
growth and development. Mutation or 
other alteration of a proto-oncogene 
can result in its conversion to a can-
cer-causing oncogene. Scientists 
now believe that, under certain cir-
cumstances, oncogenes—either by 
themselves or in conjunction with 
other genes—disrupt normal cell 
function and control of cell prolifera-
tion. 
What causes some cells to 
express or activate an oncogene, 
and what changes occur in the gene 
itself or in its regulation to make it 
dangerous, are questions being 
addressed by Gail E. Sonenshein, 
Ph.D., and her colleagues in the 
Boston University School of Medicine 
Department of Biochemistry. Such 
basic research, said Sonenshein, will 
aid in understanding how cells con-
trol their growth and will be of use in 
developing new therapies for cancer 
victims. 
Scientists have identified at least 
20 different oncogenes so far, some 
of which appear to be associated 
with particular forms of cancer. 
Sonenshein and her research associ-
ates are focusing their studies pri-
marily on one oncogene, known as 
myc, most often associated in 
humans and mice with the develop-
ment of certain tumors of the lymph 
tissue. The myc proto-oncogene has 
been found expressed in all growing 
cells tested by the BUSM research-
ers so far. 
While most of Sonenshein's stud-
ies have involved mouse cells, plans 
are under way, in conjunction with 
other investigators at Boston Univer-
sity Medical Center, to extend cur-
rent research to human tumor cells 
in an effort to develop new therapies 
for lymphoma patients. 
Sonenshein, an associate profes-
sor of biochemistry, began studying 
myc as a result of her research on 
the control of B-cell antibody produc-
tion. (B-cells primarily are responsi-
ble for producing antibodies that are 
the body's main defense against 
harmful elements.) In the course of 
her investigations using mutant B-cell 
lines, she discovered that a translo-
cation event between a pair of chro-
mosomes (an exchange of genetic 
material) caused a normally inactive 
antibody gene to become active. 
According to Sonenshein, "The 
break occurred such that a new gene 
was aligned next to the normally 
silent antibody gene and that new 
gene turned out to be an oncogene." 
Analysis of a number of different 
human and mouse B-cell tumors 
revealed, in many, a similar move-
ment of the myc oncogene from one 
chromosome to another, implicating 
this translocation in the development 
of cancer. 
As a result of this discovery, made 
simultaneously by several different 
groups, Sonenshein began investi-
gating how myc causes a cell to 
become cancerous. Experiments 
from several labs seemed to elimi-
nate the possibility of cancer caused 
simply by overproduction of the myc 
protein, and it was established that 
the products of the normal and trans-
located genes were the same. 
Therefore, the most likely remaining 
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Gail E. Sonenshein, Ph.D., examines data on oncogene activity with research assistant James E. 
McCormack. (Photo by Joan Clifford, Educational Media, BUSM) 
possibility was that the normal mech-
anism regulating myc activity was 
somehow disrupted in cancer cells, 
causing this gene to be "on" at the 
wrong time. 
"We decided to examine when 
myc goes on and when it goes off, 
and how a cell regulates this expres-
sion," said Sonenshein. 
She and colleagues at Harvard 
Medical School already have estab-
lished that when cultured, normal 
fibroblast cells stop growing, myc 
activity drops to barely detectable 
levels. When cells are actively grow-
ing, in the presence of naturally-
occurring elements called growth fac-
tors, they maintain a certain level of 
myc activity. In chemically trans-
formed fibroblast cells, even when 
growth is halted by withholding the 
necessary growth factors, myc 
remains nearly as active as if the 
cells were growing. The researchers 
concluded that the tumor cells have 
lost their ability to turn the myc gene 
off in a normal fashion. As a result, 
the change to a cancerous state may 
be due to myc being on at the wrong 
time during a cell's growth cycle. 
Questions remain, however, as to 
whether the misregulation is within 
the myc gene itself or in some other 
gene capable of controlling myc 
expression. It is known, for example, 
that some growth factors can acti-
vate the myc gene. One possible 
explanation, then, for abnormal myc 
behavior in tumor cells is that cancer 
cells produce their own growth fac-
tors, causing myc to be continually 
active. 
Experiments in conjunction with 
Judith Campisi, Ph.D., a BUSM 
assistant professor of biochemistry, 
are in progress to test whether or not 
another gene is making a growth fac-
tor-like substance that signals the 
oncogene to stay active. Preliminary 
results show that, in the absence of 
growth factors, one of the tumor cells 
tested continues to proliferate, sug-
gesting it is receiving growth factor-
like signals from within itself. Much 
more research is necessary, how-
ever, in order to understand the pre-
cise role of growth factors in myc 
regulation. 
In related experiments, Sonen-
shein plans to use sophisticated 
molecular biological approaches and 
genetic engineering techniques to 
"dissect" the myc oncogene to deter-
mine more accurately where the con-
trol elements lie. "We will introduce 
cloned myc genes into cells. If we 
retain the normal control, then we 
can start to eliminate portions of the 
gene to determine which are the cru-
cial control regions," she said. 
Along with Thomas Rothstein, 
M.D., Ph.D., an assistant professor 
of medicine, Sonenshein is planning 
experiments with human tumor cells. 
Rothstein is treating cultures of 
patients' B-cells with antibodies to 
see whether or not the cells stop 
proliferating. He is finding that B-cells 
from some patients respond to anti-
body treatment in a manner similar 
to the way the mouse B-cells 
responded in earlier experiments, 
that is, they stop growing. However, 
he has some samples that do not 
respond to the treatment and others 
that even begin to grow more rapidly. 
"We feel these differences may 
relate to alterations in the myc gene, 
and we currently are testing this pos-
sibility," said Sonenshein. 
Other researchers who have been 
involved in the myc oncogene 
research are Ann Marshak-Rothstein, 
Ph.D., an assistant professor of 
microbiology at BUSM, former BUSM 
researchers Michael Dean, Ph.D., 
and Rachael B. Kent, Ph.D., and 
doctoral students Vincent H. Pepe 
and James E. McCormack. Sonen-
shein's research is supported by 
funds from the National Institutes of 
Health. 
— Caroline H. Lupfer 
Suggested Further Readings 
1. Bishop, J.M.: Cellular oncogenes and retro-
viruses. Ann. Rev. Biochem. 52: 301-354, 
1983. 
2. Campisi, J. et al: Cell-cycle control of c-myc 
but not c-ras expression is lost following 
chemical transformation. Cell 36: 241-247, 
1984. 
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Aging study... 
continued from page 1 
Vokonas, the study's fourth director. 
"We want to explain how a 30-
year-old becomes a 70-year-old," 
said Vokonas, who is an associate 
professor of medicine at BUSM and 
a member of the Section of Preven-
tive Medicine and Epidemiology. "We 
recognize many of the biomedical 
markers that characterize aging, but 
what we want to find out is how 
?^  these processes work and how they 
interact with disease. There really is 
only limited information regarding the 
patterns of normal aging." 
As might be expected from a study 
entering its 20th year, the NAS rilready has yielded much informa-ion. More than 150 articles and book 
chapters based on data from the 
study have been published in scien-
tific and technical journals worldwide. 
For example, the findings have elic-
ited substantial information about: 
• Cardiovascular disease: Serial 
changes in ECGs can be predictive 
of higher rates of heart attack, 
ischemic heart disease and develop-
ment of hypertension. Serial changes 
in blood lipids (cholesterol and tri-
glycerides) over time are more pre-
dictive of ischemic heart disease 
than absolute values. 
• Physical anthropometry of the 
human body: Repeated measure-
ments of body dimensions have 
shown that a progressive decrease 
in height occurs with advancing age 
due to compression of the interverte-
bral spaces. Body weight increases 
until age 55 and decreases after age 
65. Computerized tomographic scan-
ning studies have demonstrated that 
this decrease is largely due to a 
decline in the amount of lean tissue 
X^-r^ (composed primarily of muscle), 
leading to an increase in the percent-
age of fat. Findings also have shown 
that the amount of fatty tissue is 
related to various diseases, including 
heart disease, and its distribution is 
indicative of the risk of diabetes. 
Epidemiologist David Sparrow, M.A., in lab coat, administers a test of pulmonary function to 
Normative Aging Study participant Wiiiiam J. Caiiahan. (Photo by Lewis A. Giass, Educational 
Media, BUSM) 
• Smoking and pulmonary func-
tion: One 10-year study has shown 
that the significant normal decline in 
pulmonary function in aging men is 
considerably greater in those who 
smoke. Change in pulmonary func-
tion for quitters of at least 10 years is 
much closer to that of those who 
have never smoked. 
• Alcohol consumption and behav-
ior: Ongoing studies of drinking 
behaviors have shown that social 
contexts for drinking are important 
predictors of alcohol consumption 
levels and the extent of problem 
drinking. Also, data have demon-
strated no real decline over nine 
years in consumption levels or rates 
of problem drinking. Retirement 
seems to have little effect on drinking 
behaviors. 
The NAS evolved from an earlier 
study of Spanish-American War Vet-
erans, ages 80 through 90. The NAS 
participants are nearly all veterans 
who at the outset of the study were 
aged 20 through 81 . They return to 
the VA Outpatient Clinic in Boston 
for medical examinations every five 
years (every three years after age 
52). The mean age of the partici-
pants when the study began 20 
years ago was 42; now it is approxi-
mately 60. 
"The NAS has no defined end-
point," said Vokonas. "It extends for 
the lifetime of its participants. We 
want to examine the whole concept 
of aging as an essential develop-
mental phenomenon of life, and ide-
ally, be able to indicate which partici-
pants are aging normally and which 
will be more prone to disease than 
others." 
According to Vokonas, the NAS 
uses two kinds of investigative mech-
anisms to gather necessary informa-
tion about participants. Core studies 
involve all participants, and include a 
comprehensive physical history and 
examination, electrocardiograms, 
chest and hand films, pulmonary 
function measurements, tests for 
special senses such as eye and ear 
function, anthropometry (the mea-
surement of different body dimen-
sions) and a battery of biochemical 
tests. 
Special projects involve selected 
groups within the study. "Special 
projects cover a range of subjects, 
from the strictly biomedical to the 
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social and emotional," said Vokonas. 
"These projects allow us to take an 
in-depth look at a given function or 
activity." Special projects have 
ranged from a study that monitors 
changes in the relationship between 
fat and muscle in older adults, to 
ones that investigate the physical, 
psychological and social effects of 
such life changes as retirement. 
According to Vokonas, the so-
called longitudinal design of the NAS 
helps to give the study its unique 
perspective. Longitudinal studies 
examine the same subjects as they 
age over an extended period of time, 
as opposed to cross-sectional stud-
ies, which investigate a group of sub-
jects of varied ages during a brief 
period of time. 
"A simple example illustrates this 
difference," Vokonas explained. "We 
know that height decreases with 
advancing age, but also that a previ-
ous generation of men was shorter 
than they are now. Repeated mea-
surements in the same individual 
over an extended period of time in a 
longitudinal study allow us to deter-
mine the decrement in height related 
to aging alone, and permits delinea-
tion of this from generational or 
cohort differences. In contrast, a 
cross-sectional study will reveal that 
height is lower in older individuals 
but cannot account for generational 
differences." 
Another bonus of a longitudinal 
study, he said, is that its ability to 
focus on individuals rather than 
groups allows it to account for the 
extreme variability in health of older 
people. "The variation in health and 
disease gets much wider with 
aging—extraordinarily so," Vokonas 
said. "Test a group of 20-year-olds, 
and many of the tests will reveal a 
narrow range of results, but test a 
group of 70-year-olds, and there will 
be a much wider range of results for 
whatever parameter is tested." 
In the future, Vokonas plans some 
minor modifications of the study's 
design. "As a clinician and cardiolo-
gist, I would like to see the study's 
biomedical domains strengthened. In 
addition, we will be expanding 
research concerning neuropsycho-
logical function and cognitive perfor-
mance." Vokonas also is planning 
collaborative studies with other 
BUSM researchers, including col-
leagues from the BUSM Department 
of Medicine, School of Public Health 
and the University's Gerontology 
Center. 
Vokonas said he hopes the study, 
in addition to providing a comprehen-
sive profile of the aging process, will 
produce greater knowledge about 
how to achieve a more fulfilling life in 
the later years. 
"We're all going to age anyway, 
whether we like it or not—we might 
as well adopt those measures now 
that will likely make those years 
happy and health ones." 
Vokonas said he feels strongly 
about the ultimate value of the Nor-
mative Aging Study. "The VA pre-
dicts that there will be eight million 
veterans over the age of 65 by the 
year 2000—this is in contrast to 
three million currently. This organiza-
tion alone may have to triple its 
resources to take care of these indi-
viduals. The greying of America is 
coming, and it's looming like a large 
cloud on the horizon bringing a host 
of problems concerning the care of 
elderly that must be addressed. 
There will be no end to the impor-
tance of this and other studies, or to 
these problems and solutions." 
— Marilyn J. Davis 
Suggested Further Readings 
1. Bosse', R. et al: The Veterans Administra-
tion Normative Aging Study, in: Handbook 
of Longitudinal Research, Vol. 2, Teenage 
and Adult Cohorts. Mednick S.A., Harway 
M. and Finello K.M. (Eds.) Praeger, New 
York, 1984. 
2. Borkan, G.A. et al: Physical anthropological 
approaches to aging. Yearbook of Physical 
Anthropology 25: 181-202, 1982. 
3. Glynn, R. et al: Changes in cholesterol and 
triglyceride as predictors of ischemic heart 
disease in men. Circulation 66: 724-731, 
1982. 
4. Sparrow, D. et al: The relationship of the 
baseline electrocardiogram to blood pres-
sure change. JAMA 250: 1285-1288, 1983. 
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